Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.

In a Phase 1 study, MGL‐3196 dosed at 50 mg per day or higher for 2 weeks significantly reduced LDL‐C by 30% and showed a trend for decreased TG. 158 A Phase 2 trial in patients with biopsy‐proven NASH revealed that resmetirom treatment resulted in a significant reduction in hepatic fat content as well as in multiple pro‐atherogenic proteins and lipids including LDL‐C, apoB, TG, apolipoprotein CIII, lipoprotein (a), small dense LDL particles and large VLDL. 159 Notably, resmetirom is one of the few potential therapeutics for NASH that has been shown to reduce lipoprotein (a), a lipoprotein closely associated with atherogenic risk and CVD. 3.13.

also in 53,322 other papers